Published in BMC Cancer on June 23, 2006
EpCAM CAR-T for Treatment of Nasopharyngeal Carcinoma and Breast Cancer | NCT02915445
EpCAM (CD326) finding its role in cancer. Br J Cancer (2007) 2.98
High expression of TROP2 correlates with poor prognosis in pancreatic cancer. Br J Cancer (2008) 1.56
Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies. Cancer Cell Int (2010) 0.96
A genome-wide expression analysis identifies a network of EpCAM-induced cell cycle regulators. Br J Cancer (2008) 0.94
Expression of the GA733 gene family and its relationship to prognosis in pulmonary adenocarcinoma. Virchows Arch (2010) 0.94
Overexpression of epithelial cell adhesion molecule protein is associated with favorable prognosis in an unselected cohort of ovarian cancer patients. J Cancer Res Clin Oncol (2014) 0.94
High EpCAM expression is linked to proliferation and lauren classification in gastric cancer. BMC Res Notes (2013) 0.93
Heterodimeric bispecific single-chain variable-fragment antibodies against EpCAM and CD16 induce effective antibody-dependent cellular cytotoxicity against human carcinoma cells. Cancer Biother Radiopharm (2013) 0.93
A phase I clinical study of VB4-845: weekly intratumoral administration of an anti-EpCAM recombinant fusion protein in patients with squamous cell carcinoma of the head and neck. Drug Des Devel Ther (2009) 0.93
Expression of EpCAM(MF) and EpCAM(MT) variants in human carcinomas. J Clin Pathol (2014) 0.91
Expression and prognostic roles of Eag1 in resected esophageal squamous cell carcinomas. Dig Dis Sci (2007) 0.90
High interstitial fluid pressure is associated with low tumour penetration of diagnostic monoclonal antibodies applied for molecular imaging purposes. PLoS One (2012) 0.88
Using DNA aptamer probe for immunostaining of cancer frozen tissues. Anal Chem (2015) 0.84
PSMA, EpCAM, VEGF and GRPR as imaging targets in locally recurrent prostate cancer after radiotherapy. Int J Mol Sci (2014) 0.84
Validation of esophageal squamous cell carcinoma candidate genes from high-throughput transcriptomic studies. Am J Cancer Res (2013) 0.83
Using aptamers to elucidate esophageal cancer clinical samples. Sci Rep (2015) 0.78
Epithelial cell adhesion molecule is expressed in a subset of sarcomas and correlates to the degree of cytological atypia in leiomyosarcomas. Mol Clin Oncol (2014) 0.78
Epithelial cell adhesion molecule in human hepatocellular carcinoma cell lines: a target of chemoresistence. BMC Cancer (2016) 0.77
Detection of soluble EpCAM (sEpCAM) in malignant ascites predicts poor overall survival in patients treated with catumaxomab. Oncotarget (2015) 0.75
Expression of natriuretic peptide receptor-A in esophageal squamous cell carcinomas and the relationship with tumor invasion and migration. World J Surg Oncol (2014) 0.75
Cancer statistics, 2005. CA Cancer J Clin (2005) 25.65
Esophageal cancer. N Engl J Med (2003) 15.23
The biology of the 17-1A antigen (Ep-CAM). J Mol Med (Berl) (1999) 3.94
Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet (2002) 3.45
Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group. Lancet (1994) 3.24
Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule. J Cell Biol (1994) 2.84
Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study. Lancet (2002) 2.78
Bayesian information criterion for censored survival models. Biometrics (2000) 2.75
The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation. Oncogene (2004) 2.67
Neoadjuvant chemoradiotherapy for esophageal carcinoma: a meta-analysis. Surgery (2005) 2.40
Epithelial cell adhesion molecule (Ep-CAM) modulates cell-cell interactions mediated by classic cadherins. J Cell Biol (1997) 2.27
High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Res Treat (2004) 2.14
EpCAM: A new therapeutic target for an old cancer antigen. Cancer Biol Ther (2003) 2.04
Ep-CAM overexpression in breast cancer as a predictor of survival. Lancet (2000) 1.94
The epithelial cell adhesion molecule (Ep-CAM) as a morphoregulatory molecule is a tool in surgical pathology. Am J Pathol (2003) 1.68
Esophageal cancer: the mode of lymphatic tumor cell spread and its prognostic significance. J Clin Oncol (2001) 1.67
Colorectal carcinoma invasion inhibition by CO17-1A/GA733 antigen and its murine homologue. J Natl Cancer Inst (1998) 1.61
Evidence for a role of the epithelial glycoprotein 40 (Ep-CAM) in epithelial cell-cell adhesion. Cell Adhes Commun (1994) 1.58
Overexpression of epithelial cell adhesion molecule antigen in gallbladder carcinoma is an independent marker for poor survival. Clin Cancer Res (2004) 1.46
Characterization and chromosomal assignment of a human cell surface antigen defined by the monoclonal antibody AUAI. Int J Cancer (1986) 1.45
Loss of Ep-CAM (CO17-1A) expression predicts survival in patients with gastric cancer. Br J Cancer (2005) 1.38
Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis. BMC Med (2004) 1.33
Cytoplasmic tail regulates the intercellular adhesion function of the epithelial cell adhesion molecule. Mol Cell Biol (1998) 1.32
Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct. Cancer Res (2005) 1.28
Epithelial cell adhesion molecule (KSA) expression: pathobiology and its role as an independent predictor of survival in renal cell carcinoma. Clin Cancer Res (2004) 1.27
In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment. Int J Cancer (2002) 1.26
Immunotherapy of malignant ascites with trifunctional antibodies. Int J Cancer (2005) 1.22
Immunohistochemical assessment of individual tumor cells in lymph nodes of patients with non-small-cell lung cancer. J Clin Oncol (1994) 1.18
Characterization of chromosome 9 deletions in transitional cell carcinoma by microsatellite assay. Hum Mol Genet (1993) 1.07
The expression of Ep-CAM (17-1A) in squamous cell cancers of the lung. Hum Pathol (2000) 1.03
Assignment of TACSTD1 (alias TROP1, M4S1) to human chromosome 2p21 and refinement of mapping of TACSTD2 (alias TROP2, M1S1) to human chromosome 1p32 by in situ hybridization. Cytogenet Cell Genet (2001) 1.02
Micrometastasis detection and treatment with monoclonal antibodies. Curr Top Microbiol Immunol (1996) 1.01
Adjuvant therapy with edrecolomab versus observation in stage II colon cancer: a multicenter randomized phase III study. Onkologie (2005) 0.97
Opsonization with a trifunctional bispecific (alphaCD3 x alphaEpCAM) antibody results in efficient lysis in vitro and in vivo of EpCAM positive tumor cells by cytotoxic T lymphocytes. Int J Oncol (2004) 0.96
Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a clinical practice guideline. BMC Cancer (2004) 0.96
Malignant potential and cytogenetic characteristics of occult disseminated tumor cells in esophageal cancer. Cancer Res (2000) 0.91
Minimal residual disease in non-small-cell lung cancer. Semin Surg Oncol (2001) 0.85
Combined treatment of metastatic breast cancer (MBC) by high-dose chemotherapy (HDCT) and bispecific antibodies: a pilot study. Anticancer Res (2005) 0.81
Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur Urol (2010) 4.11
Direct genetic analysis of single disseminated cancer cells for prediction of outcome and therapy selection in esophageal cancer. Cancer Cell (2008) 3.01
Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol (2003) 2.72
Prevalence of a tertiary Gleason grade and its impact on adverse histopathologic parameters in a contemporary radical prostatectomy series. Eur Urol (2008) 2.72
Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol (2010) 2.66
International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J Clin Oncol (2002) 2.51
Validation of the contemporary epstein criteria for insignificant prostate cancer in European men. Eur Urol (2007) 2.50
Marked gene transcript level alterations occur early during radical prostatectomy. Eur Urol (2007) 2.41
The contemporary concept of significant versus insignificant prostate cancer. Eur Urol (2011) 2.29
Frozen section for the management of intraoperatively detected palpable tumor lesions during nerve-sparing scheduled radical prostatectomy. Eur Urol (2006) 2.21
Occult disseminated tumor cells in lymph nodes of patients with gastric carcinoma. A critical appraisal of assessment and relevance. Langenbecks Arch Surg (2008) 2.14
Robust microRNA stability in degraded RNA preparations from human tissue and cell samples. Clin Chem (2010) 1.99
Development and internal validation of a nomogram predicting the probability of prostate cancer Gleason sum upgrading between biopsy and radical prostatectomy pathology. Eur Urol (2005) 1.97
A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol (2003) 1.96
Development and external validation of an extended 10-core biopsy nomogram. Eur Urol (2006) 1.90
ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin Cancer Res (2011) 1.75
Portal vein embolization and autologous CD133+ bone marrow stem cells for liver regeneration: initial experience. Radiology (2007) 1.74
Pathology of peliosis. Forensic Sci Int (2005) 1.68
Development and split-sample validation of a nomogram predicting the probability of seminal vesicle invasion at radical prostatectomy. Eur Urol (2007) 1.62
Long-term clinical and biochemical follow-up in medullary thyroid carcinoma: a single institution's experience over 20 years. Ann Surg (2007) 1.62
Molecular cancer phenotype in normal prostate tissue. Eur Urol (2008) 1.58
The feasibility of prostate cancer detection by triple spectroscopy. Eur Urol (2008) 1.55
Portal application of autologous CD133+ bone marrow cells to the liver: a novel concept to support hepatic regeneration. Stem Cells (2005) 1.53
[Hemangiosarcoma after breast-conserving therapy of breast cancer: report of four cases with molecular genetic diagnosis and literature review]. Strahlenther Onkol (2011) 1.51
Clinical significance of p53 alterations in surgically treated prostate cancers. Mod Pathol (2008) 1.51
Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. Neoplasia (2013) 1.49
Currently used criteria for active surveillance in men with low-risk prostate cancer: an analysis of pathologic features. Cancer (2008) 1.48
Prostate cancers in the transition zone: Part 2; clinical aspects. BJU Int (2004) 1.46
Assessment of pathological prostate cancer characteristics in men with favorable biopsy features on predominantly sextant biopsy. Eur Urol (2008) 1.45
Can predictive models for prostate cancer patients derived in the United States of America be utilized in European patients? A validation study of the Partin tables. Eur Urol (2003) 1.44
Critical assessment of tools to predict clinically insignificant prostate cancer at radical prostatectomy in contemporary men. Cancer (2008) 1.39
The 2002 AJCC pT2 substages confer no prognostic information on the rate of biochemical recurrence after radical prostatectomy. Eur Urol (2006) 1.38
High incidence of prostate cancer detected by saturation biopsy after previous negative biopsy series. Eur Urol (2006) 1.38
Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer. Clin Cancer Res (2007) 1.36
Education and health in 22 European countries. Soc Sci Med (2006) 1.35
Neighbourhood socioeconomic status and cardiovascular risk factors: a multilevel analysis of nine cities in the Czech Republic and Germany. BMC Public Health (2007) 1.32
miRNA profiling identifies candidate mirnas for bladder cancer diagnosis and clinical outcome. J Mol Diagn (2013) 1.30
Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer. Clin Cancer Res (2010) 1.28
Reference genes for the relative quantification of microRNAs in renal cell carcinomas and their metastases. Anal Biochem (2011) 1.25
SCOMP is superior to degenerated oligonucleotide primed-polymerase chain reaction for global amplification of minute amounts of DNA from microdissected archival tissue samples. Am J Pathol (2002) 1.24
Malignant fibrous histiocytoma of the extremities and trunk: an institutional review. Surgery (2004) 1.23
Prediction of left ventricular remodeling and analysis of infarct resorption in patients with reperfused myocardial infarcts by using contrast-enhanced MR imaging. Radiology (2007) 1.21
Bevacizumab as a treatment option for radiation-induced cerebral necrosis. Strahlenther Onkol (2011) 1.20
Tumour volume and high grade tumour volume are the best predictors of pathologic stage and biochemical recurrence after radical prostatectomy. Eur J Cancer (2007) 1.19
Histopathology and clinical outcome of NF1-associated vs. sporadic malignant peripheral nerve sheath tumors. J Neurooncol (2006) 1.18
Genetic and phenotypic characterization of tumor cells derived from malignant peripheral nerve sheath tumors of neurofibromatosis type 1 patients. Neurobiol Dis (2004) 1.15
Heterogeneous proliferative potential of occult metastatic cells in bone marrow of patients with solid epithelial tumors. Proc Natl Acad Sci U S A (2002) 1.15
Surgical volume is related to the rate of positive surgical margins at radical prostatectomy in European patients. BJU Int (2006) 1.15
Identification of metastamirs as metastasis-associated microRNAs in clear cell renal cell carcinomas. Int J Biol Sci (2012) 1.14
CDC91L1 (PIG-U) is a newly discovered oncogene in human bladder cancer. Nat Med (2004) 1.14
Adult diffuse nesidioblastosis: genetically or environmentally induced? Hum Pathol (2008) 1.14
Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies. Cancer Res (2011) 1.13
Prospective validation of an algorithm with systematic sextant biopsy to predict pelvic lymph node metastasis in patients with clinically localized prostatic carcinoma. J Urol (2002) 1.12
Is year of radical prostatectomy a predictor of outcome in prostate cancer? J Urol (2004) 1.11
Suitable reference genes for relative quantification of miRNA expression in prostate cancer. Exp Mol Med (2010) 1.10
Prognosis and treatment of primary deep soft tissue sarcomas. Anticancer Res (2007) 1.10
Reference miRNAs for miRNAome analysis of urothelial carcinomas. PLoS One (2012) 1.09
Microsatellite analysis of serum DNA in patients with head and neck cancer. Int J Cancer (2004) 1.09
Influence of nerve-sparing (NS) procedure during radical prostatectomy (RP) on margin status and biochemical failure. Eur Urol (2005) 1.09
Long-term survival after surgery for primary hepatic sarcoma in adults. Arch Surg (2009) 1.08
Diffuse nesidioblastosis as a cause of hyperinsulinemic hypoglycemia in adults: a diagnostic and therapeutic challenge. Surgery (2007) 1.08
The human tumor suppressor CEACAM1 modulates apoptosis and is implicated in early colorectal tumorigenesis. Oncogene (2004) 1.07
Assessment of the enhancement in predictive accuracy provided by systematic biopsy in predicting outcome for clinically localized prostate cancer. J Urol (2004) 1.06
Neuroendocrine neoplasms of the gastrointestinal tract. Dtsch Arztebl Int (2011) 1.05
Diagnostic and prognostic potential of differentially expressed miRNAs between metastatic and non-metastatic renal cell carcinoma at the time of nephrectomy. Clin Chim Acta (2012) 1.05
Obesity does not predispose to more aggressive prostate cancer either at biopsy or radical prostatectomy in European men. Int J Cancer (2007) 1.05
Somatostatin-producing neuroendocrine tumors of the duodenum and pancreas: incidence, types, biological behavior, association with inherited syndromes, and functional activity. Endocr Relat Cancer (2008) 1.04
Subclinical coronary atherosclerosis and neighbourhood deprivation in an urban region. Eur J Epidemiol (2008) 1.03
Contemporary grading for prostate cancer: implications for patient care. Eur Urol (2012) 1.03
Adipose dipeptidyl peptidase-4 and obesity: correlation with insulin resistance and depot-specific release from adipose tissue in vivo and in vitro. Diabetes Care (2013) 1.03
Sporadic versus hereditary gastrinomas of the duodenum and pancreas: distinct clinico-pathological and epidemiological features. World J Gastroenterol (2006) 1.02
Diagnostic leukapheresis enables reliable detection of circulating tumor cells of nonmetastatic cancer patients. Proc Natl Acad Sci U S A (2013) 1.02
Extraction and processing of high quality RNA from impalpable and macroscopically invisible prostate cancer for microarray gene expression analysis. Int J Oncol (2005) 1.01
Distinct subcellular expression patterns of neutral endopeptidase (CD10) in prostate cancer predict diverging clinical courses in surgically treated patients. Clin Cancer Res (2008) 1.00
Circulating tumour-associated plasma DNA represents an independent and informative predictor of prostate cancer. BJU Int (2006) 1.00
Development and external validation of an extended repeat biopsy nomogram. J Urol (2007) 1.00
NY-CO-58/KIF2C is overexpressed in a variety of solid tumors and induces frequent T cell responses in patients with colorectal cancer. Int J Cancer (2010) 0.99
O-linked glycosylation and functional incompatibility of porcine von Willebrand factor for human platelet GPIb receptors. Xenotransplantation (2005) 0.99
Detection of tumor-specific DNA in blood and bone marrow plasma from patients with prostate cancer. Int J Cancer (2007) 0.98
Who is at risk for diagnostic discrepancies? Comparison of pre- and postmortal diagnoses in 1800 patients of 3 medical decades in East and West Berlin. PLoS One (2012) 0.98
Gene expression analysis of pancreatic cell lines reveals genes overexpressed in pancreatic cancer. Pancreatology (2005) 0.97
A validation of two preoperative nomograms predicting recurrence following radical prostatectomy in a cohort of European men. Urol Oncol (2002) 0.96
Prognostic and clinicopathological significance of survivin in colorectal cancer: a meta-analysis. PLoS One (2013) 0.96